Asterias Biotherapeutics acquires Geron's stem cell assets, cell lines

10/1/2013 | American City Business Journals

Geron agreed to sell its human embryonic stem cell assets and the rights to use certain stem cell lines to Asterias Biotherapeutics, a subsidiary of BioTime, as part of a stock swap and intellectual property deal. Asterias will get four cell lines including neurology and orthopedics lines. Geron is eligible to receive sales royalties on any products developed using its patents.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX